A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care (ROSE)

AstraZeneca

Status: Completed

Conditions: Diabetes Type II

Study type: Observational

Funder types: Industry

Identifiers

NCT01121315

NIS-CSE-DUM-2010/1

Details and patient eligibility

About

To describe the type II diabetes population in primary care with special reference to treatment, other diseases and mortality during the last decade. To test the hypothesis that the type or combination of per oral glucose lowering drugs have different effects on the risk of cardiovascular disease and diabetic complications.

Enrollment: 58,326 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type II diabetes, according to medical records, diagnosis, prescription or lab assessments

Exclusion criteria

• Patients followed by physician for less than 6 months after diagnosis of Diabetes type II

Trial design

58,326 participants in 1 patient group

1

Description:

Diabetes type II patients, according to medical records, prescriptions or lab results, followed for \>6 months after diagnosis.